MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment

Ewa A. Bartko; Maiken Mellergaard; Solveig S. Groen; Signe Holm Nielsen; Jesper Elberling; Aase Handberg; Lars K. Poulsen; Lars H. Blom; Bettina M. Jensen

doi:10.1111/all.16212

MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment

Ewa A. Bartko^*, Maiken Mellergaard, Solveig S. Groen, Signe Holm Nielsen, Jesper Elberling, Aase Handberg, Lars K. Poulsen, Lars H. Blom, Bettina M. Jensen

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › Research › peer-review

Original language	English
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	79
Issue number	9
Pages (from-to)	2558-2561
Number of pages	4
ISSN	0105-4538
DOIs	https://doi.org/10.1111/all.16212
Publication status	Published - 2024

Access to Document

10.1111/all.16212

Cite this

Bartko, E. A., Mellergaard, M., Groen, S. S., Nielsen, S. H., Elberling, J., Handberg, A., Poulsen, L. K., Blom, L. H., & Jensen, B. M. (2024). MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment. Allergy: European Journal of Allergy and Clinical Immunology, 79(9), 2558-2561. https://doi.org/10.1111/all.16212

MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment. / Bartko, Ewa A.; Mellergaard, Maiken; Groen, Solveig S.; Nielsen, Signe Holm; Elberling, Jesper; Handberg, Aase; Poulsen, Lars K.; Blom, Lars H.; Jensen, Bettina M.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, No. 9, 2024, p. 2558-2561.

Research output: Contribution to journal › Comment/debate › Research › peer-review

Bartko, Ewa A. ; Mellergaard, Maiken ; Groen, Solveig S. ; Nielsen, Signe Holm ; Elberling, Jesper ; Handberg, Aase ; Poulsen, Lars K. ; Blom, Lars H. ; Jensen, Bettina M. / MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment. In: Allergy: European Journal of Allergy and Clinical Immunology. 2024 ; Vol. 79, No. 9. pp. 2558-2561.

@article{65e538d94f47422da761c6e0ebac68a5,

title = "MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment",

author = "Bartko, {Ewa A.} and Maiken Mellergaard and Groen, {Solveig S.} and Nielsen, {Signe Holm} and Jesper Elberling and Aase Handberg and Poulsen, {Lars K.} and Blom, {Lars H.} and Jensen, {Bettina M.}",

year = "2024",

doi = "10.1111/all.16212",

language = "English",

volume = "79",

pages = "2558--2561",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley Online",

number = "9",

}

TY - JOUR

T1 - MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment

AU - Bartko, Ewa A.

AU - Mellergaard, Maiken

AU - Groen, Solveig S.

AU - Nielsen, Signe Holm

AU - Elberling, Jesper

AU - Handberg, Aase

AU - Poulsen, Lars K.

AU - Blom, Lars H.

AU - Jensen, Bettina M.

PY - 2024

Y1 - 2024

U2 - 10.1111/all.16212

DO - 10.1111/all.16212

M3 - Comment/debate

C2 - 38953463

AN - SCOPUS:85197258150

VL - 79

SP - 2558

EP - 2561

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 9

ER -